2007 Fiscal Year Final Research Report Summary
Identification of a new apoptotic pathway of radiation-induced apoptosis of human peripheral lymphocytes
| Project/Area Number |
18591382
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Radiation science
|
|---|
| Research Institution | Kochi University |
|---|
Principal Investigator |
OGAWA Yasuhiro Kochi University, Kochi Medical School, Professor (90152397)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
KOBAYASHI Toshihiko Kochi University, Kochi Medical School, Assistant (40153621)
|
|---|
| Project Period (FY) |
2006 – 2007
|
| Keywords | lymphocyte / apoptosis / mitochondria / lysosome / radiotherapy / 放射線抵抗性 / 放射線感受性 / 放射線治療 |
|---|
| Research Abstract |
Using a currently used linear accelerator we intended to inactivate peroxidase/catalase in a topical tumor tissiue by the application of hydrogen peroxide, thus re-oxygenizing the tumor tissue by the oxygen produced by the hydrogen peroxide degradation. In this way, we can convert radioresistant tumors into radiosensitive ones.
On the basis of this strategy, we have developed a new enzyme-targeted radiosensitization treatment named KORTUC I (Kochi Oxydol-Radiation Therapy for Unresectable Carcinomas, Type I), which remarkably enhances the radiotherapeutic effect on various types of superficial & locally advanced malignant neoplasms. In the method, the surface of the tumor is covered by hydrogen peroxide solution (Oxydol)-soaked gauze during each administration of radiation therapy.
Based on our clinical experiences using KORTUC I, we also developed a new radiosensitizer containing hydrogen peroxide and sodium hyaluronate for topical tumor injection for various types of tumors which are not superficially exposed (KORTUC II). KORTUC II was accepted by our local ethical committee concerning of the use for skin cancer, bone/soft tissue malignant neoplasms, breast cancer, and metastatic lymph nodes. Maximally 3 ml of the agent was injected into topical tumor tissue, one to two times per week, under an ultrasonographic guide just prior to each administration of radiation therapy.
Fifteen patients including 10 breast cancer patients were enrolled in the KORTUC II trial upon fully informed consent. Twelve of the patients showed clinically complete response by the new enzyme-targeting radiosensitization treatment (KORTUC II) without any severe complications. The method can be indicated for various types of locally advanced neoplasms.
|
